{
     "PMID": "25312280",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20150715",
     "LR": "20151119",
     "IS": "1873-7064 (Electronic) 0028-3908 (Linking)",
     "VI": "89",
     "DP": "2015 Feb",
     "TI": "Glycine transporters type 1 inhibitor promotes brain preconditioning against NMDA-induced excitotoxicity.",
     "PG": "274-81",
     "LID": "10.1016/j.neuropharm.2014.10.003 [doi] S0028-3908(14)00366-9 [pii]",
     "AB": "Brain preconditioning is a protective mechanism, which can be activated by sub-lethal stimulation of the NMDA receptors (NMDAR) and be used to achieve neuroprotection against stroke and neurodegenerative diseases models. Inhibitors of glycine transporters type 1 modulate glutamatergic neurotransmission through NMDAR, suggesting an alternative therapeutic strategy of brain preconditioning. The aim of this work was to evaluate the effects of brain preconditioning induced by NFPS, a GlyT1 inhibitor, against NMDA-induced excitotoxicity in mice hippocampus, as well as to study its neurochemical mechanisms. C57BL/6 mice (male, 10-weeks-old) were preconditioned by intraperitoneal injection of NFPS at doses of 1.25, 2.5 or 5.0 mg/kg, 24 h before intrahippocampal injection of NMDA. Neuronal death was evaluated by fluoro jade C staining and neurochemical parameters were evaluated by gas chromatography-mass spectrometry, scintillation spectrometry and western blot. We observed that NFPS preconditioning reduced neuronal death in CA1 region of hippocampus submitted to NMDA-induced excitotoxicity. The amino acids (glycine and glutamate) uptake and content were increased in hippocampus of animals treated with NFPS 5.0 mg/kg, which were associated to an increased expression of type-2 glycine transporter (GlyT2) and glutamate transporters (EAAT1, EAAT2 and EAAT3). The expression of GlyT1 was reduced in animals treated with NFPS. Interestingly, the preconditioning reduced expression of GluN2B subunits of NMDAR, whereas did not change the expression of GluN1 or GluN2A in all tested doses. Our study suggests that NFPS preconditioning induces resistance against excitotoxicity, which is associated with neurochemical changes and reduction of GluN2B-containing NMDAR expression.",
     "CI": [
          "Copyright (c) 2014 Elsevier Ltd. All rights reserved."
     ],
     "FAU": [
          "Pinto, Mauro Cunha Xavier",
          "Lima, Isabel Vieira de Assis",
          "da Costa, Flavia Lage Pessoa",
          "Rosa, Daniela Valadao",
          "Mendes-Goulart, Vania Aparecida",
          "Resende, Rodrigo Ribeiro",
          "Romano-Silva, Marco Aurelio",
          "de Oliveira, Antonio Carlos Pinheiro",
          "Gomez, Marcus Vinicius",
          "Gomez, Renato Santiago"
     ],
     "AU": [
          "Pinto MC",
          "Lima IV",
          "da Costa FL",
          "Rosa DV",
          "Mendes-Goulart VA",
          "Resende RR",
          "Romano-Silva MA",
          "de Oliveira AC",
          "Gomez MV",
          "Gomez RS"
     ],
     "AD": "INCT de Medicina Molecular, Faculdade de Medicina, Universidade Federal de Minas Gerais, Av. Alfredo Balena 190, 30130-100, Belo Horizonte, MG, Brazil; Departamento de Cirurgia, Faculdade de Medicina, Universidade Federal de Minas Gerais, Av. Alfredo Balena, 190, 30130-100, Belo Horizonte, MG, Brazil. Electronic address: mauroxavier@ufmg.br. Departamento de Farmacologia, Instituto de Ciencia Biologicas, Universidade Federal de Minas Gerais, Av. Antonio Carlos, 6627, 31270-901, Belo Horizonte, MG, Brazil. INCT de Medicina Molecular, Faculdade de Medicina, Universidade Federal de Minas Gerais, Av. Alfredo Balena 190, 30130-100, Belo Horizonte, MG, Brazil; Departamento de Cirurgia, Faculdade de Medicina, Universidade Federal de Minas Gerais, Av. Alfredo Balena, 190, 30130-100, Belo Horizonte, MG, Brazil. INCT de Medicina Molecular, Faculdade de Medicina, Universidade Federal de Minas Gerais, Av. Alfredo Balena 190, 30130-100, Belo Horizonte, MG, Brazil. Departamento de Bioquimica e Imunologia, Instituto de Ciencia Biologicas, Universidade Federal de Minas Gerais, Av. Antonio Carlos, 6627, 31270-901, Belo Horizonte, MG, Brazil. Departamento de Bioquimica e Imunologia, Instituto de Ciencia Biologicas, Universidade Federal de Minas Gerais, Av. Antonio Carlos, 6627, 31270-901, Belo Horizonte, MG, Brazil. INCT de Medicina Molecular, Faculdade de Medicina, Universidade Federal de Minas Gerais, Av. Alfredo Balena 190, 30130-100, Belo Horizonte, MG, Brazil. Departamento de Farmacologia, Instituto de Ciencia Biologicas, Universidade Federal de Minas Gerais, Av. Antonio Carlos, 6627, 31270-901, Belo Horizonte, MG, Brazil. Instituto de Ensino e Pesquisa da Santa Casa de Belo Horizonte, R. Domingos Vieira, 590, Belo Horizonte, MG, Brazil. Departamento de Cirurgia, Faculdade de Medicina, Universidade Federal de Minas Gerais, Av. Alfredo Balena, 190, 30130-100, Belo Horizonte, MG, Brazil.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20141013",
     "PL": "England",
     "TA": "Neuropharmacology",
     "JT": "Neuropharmacology",
     "JID": "0236217",
     "RN": [
          "0 (Excitatory Amino Acid Agonists)",
          "0 (Fluoresceins)",
          "0 (Glycine Plasma Membrane Transport Proteins)",
          "0",
          "(N-(3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)-3-(4'-phenylphenoxy)propyl)sarcosine",
          ")",
          "0 (fluoro jade)",
          "10028-17-8 (Tritium)",
          "3KX376GY7L (Glutamic Acid)",
          "6384-92-5 (N-Methylaspartate)",
          "TE7660XO1C (Glycine)",
          "Z711V88R5F (Sarcosine)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Disease Models, Animal",
          "Dose-Response Relationship, Drug",
          "Drug Administration Schedule",
          "Excitatory Amino Acid Agonists/*toxicity",
          "Fluoresceins",
          "Gas Chromatography-Mass Spectrometry",
          "Gene Expression Regulation/drug effects",
          "Glutamic Acid/metabolism",
          "Glycine/metabolism",
          "Glycine Plasma Membrane Transport Proteins/*antagonists & inhibitors",
          "Hippocampus/drug effects/injuries",
          "Male",
          "Mice",
          "Mice, Inbred C57BL",
          "N-Methylaspartate/*toxicity",
          "*Neurotoxicity Syndromes/etiology/pathology/prevention & control",
          "Sarcosine/administration & dosage/*analogs & derivatives",
          "Time Factors",
          "Tritium/metabolism"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "Brain preconditioning",
          "Glycine transporter type 1",
          "Neuroprotection",
          "Neurotransmission"
     ],
     "EDAT": "2014/10/15 06:00",
     "MHDA": "2015/07/16 06:00",
     "CRDT": [
          "2014/10/15 06:00"
     ],
     "PHST": [
          "2014/05/20 00:00 [received]",
          "2014/09/07 00:00 [revised]",
          "2014/10/01 00:00 [accepted]",
          "2014/10/15 06:00 [entrez]",
          "2014/10/15 06:00 [pubmed]",
          "2015/07/16 06:00 [medline]"
     ],
     "AID": [
          "S0028-3908(14)00366-9 [pii]",
          "10.1016/j.neuropharm.2014.10.003 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Neuropharmacology. 2015 Feb;89:274-81. doi: 10.1016/j.neuropharm.2014.10.003. Epub 2014 Oct 13.",
     "term": "hippocampus"
}